PROCEPT BioRobotics Corp

PROCEPT BioRobotics Corp is a surgical robotics company focused on developing transformative solutions in urology to advance patient care. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System. These are advanced, image-guided, surgical robotic systems designed for minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease, affecting approximately 40 million men in the United States. Each robotic system uses a single-use disposable handpiece to deliver the company's proprietary Aquablation therapy. This therapy combines real-time, multi-dimensional imaging, personalized treatment planning, automated robotics, and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. The robotic systems are designed to enable consistent and reproducible BPH surgery outcomes. Aquablation therapy aims to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH, independent of prostate size and shape, and delivers resection independent of surgeon experience. The company has developed a significant body of clinical evidence, including nine clinical studies and over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy. As of December 31, 2025, PROCEPT BioRobotics Corp had an installed base of 912 AquaBeam Robotic Systems and HYDROS Robotic Systems globally, with 718 of these located in the United States. BPH is the non-malignant enlargement of the prostate gland, which can obstruct or restrict urine flow and lead to LUTS.